The long-term outlook for LENZ Therapeutics stock is anchored on the successful commercial adoption and nationwide market penetration of its flagship FDA-approved presbyopia treatment, VIZZ. Financial analysts project that sustained revenue growth, expanded eyecare professional partnerships, and potential international licensing agreements will serve as primary catalysts for future equity valuation, though execution speed and competitive market pressures remain critical variables.